COLL News and Press, Collegium Pharmaceutical Inc. From 11/07/23

2023-11-07 22:15:13 ET Collegium Pharmaceutical, Inc. (COLL) Q3 2023 Earnings Conference Call November 7, 2023 04:30 PM ET Company Participants Christopher James - Vice President, Investor Relations Joe Ciaffoni - President and CEO Colleen Tupper - Chief Financia...

2023-11-07 16:08:29 ET More on Collegium Pharmaceutical Collegium Pharmaceutical: Delivering On Promises Collegium Pharmaceutical: Pipeline Continues As Share Buyback Initiates With 30% Returns On Capital Deployed At 4.4x Earnings, Collegium Is A Buy Collegiu...

– Q3’23 Net Revenue of $136.7 Million, Up 8% Year-over-Year – – Q3’23 GAAP Net Income of $20.6 Million vs. Q3’22 GAAP Net Income of $0.5 Million – – Record Q3’23 Adjusted EBITDA of $89.4 Million, Up 19% Year-over-Yea...

Weyco Group Inc. (WEYS) is expected to report for Q1 2024 Gladstone Land Corporation (LAND) is expected to report $0.16 for Q3 2023 PlayAGS Inc. (AGS) is expected to report $0.01 for Q3 2023 Ardmore Shipping Corporation (ASC) is expected to report $0.43 for Q3 2023 Sage Therapeuti...

Collegium Pharmaceutical Inc. (COLL) is expected to report $1.11 for Q3 2023

2023-10-24 14:59:23 ET Summary Today, we revisit Collegium Pharmaceutical, Inc., which has seen a 30% increase in its stock price since our last look at it in June 2022. Collegium Pharmaceutical has done a good job integrating Belbuca into its product portfolio, paying down debt a...

STOUGHTON, Mass., Oct. 24, 2023 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company committed to improving the lives of people living with serious medical conditions, today announced that it will report third quarter 2023 ...

STOUGHTON, Mass., Aug. 28, 2023 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company committed to improving the lives of people living with serious medical conditions, today announced that 10 poster presentations highlighti...

2023-08-24 12:38:29 ET More on Collegium Pharmaceutical Collegium Pharmaceutical: Pipeline Continues As Share Buyback Initiates With 30% Returns On Capital Deployed At 4.4x Earnings, Collegium Is A Buy Collegium Pharmaceutical, Inc. ( COLL ) Q2 2023 Earnings Ca...

STOUGHTON, Mass., Aug. 24, 2023 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company committed to improving the lives of people living with serious medical conditions, today announced that the U.S. Food and Drug Administrat...